<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">35492218</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2589-0042</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>iScience</Title>
          <ISOAbbreviation>iScience</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.</ArticleTitle>
        <Pagination>
          <StartPage>104293</StartPage>
          <MedlinePgn>104293</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">104293</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2022.104293</ELocationID>
        <Abstract>
          <AbstractText>The nucleoside analog N4-hydroxycytidine (NHC) is the active metabolite of the prodrug molnupiravir, which has been approved for the treatment of COVID-19. SARS-CoV-2 incorporates NHC into its RNA, resulting in defective virus genomes. Likewise, inhibitors of dihydroorotate dehydrogenase (DHODH) reduce virus yield upon infection, by suppressing the cellular synthesis of pyrimidines. Here, we show that NHC and DHODH inhibitors strongly synergize in the inhibition of SARS-CoV-2 replication <i>in vitro</i>. We propose that the lack of available pyrimidine nucleotides upon DHODH inhibition increases the incorporation of NHC into nascent viral RNA. This concept is supported by the rescue of virus replication upon addition of pyrimidine nucleosides to the media. DHODH inhibitors increased the antiviral efficiency of molnupiravir not only in organoids of human lung, but also in Syrian Gold hamsters and in K18-hACE2 mice. Combining molnupiravir with DHODH inhibitors may thus improve available therapy options for COVID-19.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stegmann</LastName>
            <ForeName>Kim M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus von Liebig Weg 11, 37077 Göttingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dickmanns</LastName>
            <ForeName>Antje</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus von Liebig Weg 11, 37077 Göttingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heinen</LastName>
            <ForeName>Natalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blaurock</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karrasch</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus von Liebig Weg 11, 37077 Göttingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Breithaupt</LastName>
            <ForeName>Angele</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klopfleisch</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Veterinary Pathology, Freie Universität Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uhlig</LastName>
            <ForeName>Nadja</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eberlein</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Issmail</LastName>
            <ForeName>Leila</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herrmann</LastName>
            <ForeName>Simon T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biochemistry, Ruhr University Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreieck</LastName>
            <ForeName>Amelie</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Immunic AG, Gräfelfing, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peelen</LastName>
            <ForeName>Evelyn</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Immunic AG, Gräfelfing, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kohlhof</LastName>
            <ForeName>Hella</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Immunic AG, Gräfelfing, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sadeghi</LastName>
            <ForeName>Balal</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Greifswald-Insel Riems, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riek</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Friedrich-Loeffler-Institut, Institute of Animal Welfare and Animal Husbandry, Celle, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Speakman</LastName>
            <ForeName>John R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biological and Environmental Sciences, University of Aberdeen, Aberdeen, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Groß</LastName>
            <ForeName>Uwe</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Microbiology and Virology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Göttingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Görlich</LastName>
            <ForeName>Dirk</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vitt</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Immunic AG, Gräfelfing, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Müller</LastName>
            <ForeName>Thorsten</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biochemistry, Ruhr University Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Psychiatric Phenomics and Genomics (IPPG), Organoid Laboratory, University Hospital, LMU Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grunwald</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pfaender</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balkema-Buschmann</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dobbelstein</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus von Liebig Weg 11, 37077 Göttingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>iScience</MedlineTA>
        <NlmUniqueID>101724038</NlmUniqueID>
        <ISSNLinking>2589-0042</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drugs</Keyword>
        <Keyword MajorTopicYN="N">Virology</Keyword>
      </KeywordList>
      <CoiStatement>AS, HK, EP, and DV are employees of Immunic AG and own shares and/or stock-options of the parent company of Immunic AG, Immunic Inc. Some of the Immunic AG employees also hold patents for the Immunic compounds described in this manuscript (WO2012/001,148, WO03006425). KMS, AD, and MD are employees of University Medical Center Göttingen, which has signed a License Agreement with Immunic AG covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infections, including COVID-19 (inventors: MD, KMS, and AD). The other authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35492218</ArticleId>
        <ArticleId IdType="pmc">PMC9035612</ArticleId>
        <ArticleId IdType="doi">10.1016/j.isci.2022.104293</ArticleId>
        <ArticleId IdType="pii">S2589-0042(22)00563-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abdelnabi R., Foo C.S., De Jonghe S., Maes P., Weynand B., Neyts J. Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model. J. Infect. Dis. 2021;224:749–753. doi: 10.1093/infdis/jiab361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab361</ArticleId>
            <ArticleId IdType="pmc">PMC8408768</ArticleId>
            <ArticleId IdType="pubmed">34244768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C., et al.  Small-molecule antiviral β-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93:e01348-19. doi: 10.1128/jvi.01348-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jvi.01348-19</ArticleId>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J., Sidwell R.W. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antivir. Chem. Chemother. 2004;15:15–22. doi: 10.1177/095632020401500102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/095632020401500102</ArticleId>
            <ArticleId IdType="pubmed">15074711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al.  Remdesivir for the treatment of COVID-19 - final report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/nejmoa2007764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa2007764</ArticleId>
            <ArticleId IdType="pmc">PMC7262788</ArticleId>
            <ArticleId IdType="pubmed">32445440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bliss C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 1939;26:585–615. doi: 10.1111/j.1744-7348.1939.tb06990.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1744-7348.1939.tb06990.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calistri A., Luganini A., Mognetti B., Elder E., Sibille G., Conciatori V., Del Vecchio C., Sainas S., Boschi D., Montserrat N., et al.  The new generation hDHODH inhibitor MEDS433 hinders the In vitro replication of SARS-CoV-2 and other human coronaviruses. Microorganisms. 2021;9:1731. doi: 10.3390/microorganisms9081731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/microorganisms9081731</ArticleId>
            <ArticleId IdType="pmc">PMC8398173</ArticleId>
            <ArticleId IdType="pubmed">34442810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caruso A., Caccuri F., Bugatti A., Zani A., Vanoni M., Bonfanti P., Cazzaniga M.E., Perno C.F., Messa C., Alberghina L. Methotrexate inhibits SARS-CoV-2 virus replication “in vitro”. J. Med. Virol. 2021;93:1780–1785. doi: 10.1002/jmv.26512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26512</ArticleId>
            <ArticleId IdType="pmc">PMC7891346</ArticleId>
            <ArticleId IdType="pubmed">32926453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corman V.M., Landt O., Kaiser M., Molenkamp R., Meijer A., Chu D.K., Bleicker T., Brünink S., Schneider J., Schmidt M.L., et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045. doi: 10.2807/1560-7917.es.2020.25.3.2000045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2807/1560-7917.es.2020.25.3.2000045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costantini V.P., Whitaker T., Barclay L., Lee D., McBrayer T.R., Schinazi R.F., Vinjé J. Antiviral activity of nucleoside analogues against norovirus. Antivir. Ther. 2012;17:981–991. doi: 10.3851/imp2229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3851/imp2229</ArticleId>
            <ArticleId IdType="pmc">PMC7751060</ArticleId>
            <ArticleId IdType="pubmed">22910194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 2021;6:11–18. doi: 10.1038/s41564-020-00835-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-020-00835-2</ArticleId>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y.N., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000;6:1375–1379. doi: 10.1038/82191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/82191</ArticleId>
            <ArticleId IdType="pubmed">11100123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 2004;68:2301–2315. doi: 10.1016/j.bcp.2004.07.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2004.07.039</ArticleId>
            <ArticleId IdType="pubmed">15548377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks S.G., Overbaugh J., Phillips A., Buchbinder S. HIV infection. Nat. Rev. Dis. Primers. 2015;1:15035. doi: 10.1038/nrdp.2015.35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2015.35</ArticleId>
            <ArticleId IdType="pubmed">27188527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doherty P.C. What have we learnt so far from COVID-19? Nat. Rev. Immunol. 2021;21:67–68. doi: 10.1038/s41577-021-00498-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-021-00498-y</ArticleId>
            <ArticleId IdType="pmc">PMC7805424</ArticleId>
            <ArticleId IdType="pubmed">33442033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorn I., Klich K., Arauzo-Bravo M.J., Radstaak M., Santourlidis S., Ghanjati F., Radke T.F., Psathaki O.E., Hargus G., Kramer J., et al.  Erythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin. Haematologica. 2015;100:32–41. doi: 10.3324/haematol.2014.108068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2014.108068</ArticleId>
            <ArticleId IdType="pmc">PMC4281310</ArticleId>
            <ArticleId IdType="pubmed">25326431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehteshami M., Tao S., Zandi K., Hsiao H.M., Jiang Y., Hammond E., Amblard F., Russell O.O., Merits A., Schinazi R.F. Characterization of β-d-N(4)-hydroxycytidine as a novel inhibitor of Chikungunya virus. Antimicrob. Agents Chemother. 2017;61 doi: 10.1128/aac.02395-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.02395-16</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fajgenbaum D.C., June C.H. Cytokine storm. N. Engl. J. Med. 2020;383:2255–2273. doi: 10.1056/nejmra2026131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmra2026131</ArticleId>
            <ArticleId IdType="pmc">PMC7727315</ArticleId>
            <ArticleId IdType="pubmed">33264547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoso Y.D., Brooks J.B.B. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev. Clin. Pharmacol. 2015;8:315–320. doi: 10.1586/17512433.2015.1019343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/17512433.2015.1019343</ArticleId>
            <ArticleId IdType="pubmed">25712857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francis M.E., Goncin U., Kroeker A., Swan C., Ralph R., Lu Y., Etzioni A.L., Falzarano D., Gerdts V., Machtaler S., et al.  SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney. PLoS Pathog. 2021;17:e1009705. doi: 10.1371/journal.ppat.1009705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1009705</ArticleId>
            <ArticleId IdType="pmc">PMC8282065</ArticleId>
            <ArticleId IdType="pubmed">34265022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georg P., Astaburuaga-Garcia R., Bonaguro L., Brumhard S., Michalick L., Lippert L.J., Kostevc T., Gabel C., Schneider M., Streitz M., et al.  Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022;185:493–512.e25. doi: 10.1016/j.cell.2021.12.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2021.12.040</ArticleId>
            <ArticleId IdType="pmc">PMC8712270</ArticleId>
            <ArticleId IdType="pubmed">35032429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldman J.D., Lye D.C.B., Hui D.S., Marks K.M., Bruno R., Montejano R., Spinner C.D., Galli M., Ahn M.Y., Nahass R.G., et al.  Remdesivir for 5 or 10 days in patients with severe COVID-19. N. Engl. J. Med. 2020;383:1827–1837. doi: 10.1056/nejmoa2015301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa2015301</ArticleId>
            <ArticleId IdType="pmc">PMC7377062</ArticleId>
            <ArticleId IdType="pubmed">32459919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297:100770. doi: 10.1016/j.jbc.2021.100770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId>
            <ArticleId IdType="pmc">PMC8110631</ArticleId>
            <ArticleId IdType="pubmed">33989635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groß R., Conzelmann C., Müller J.A., Stenger S., Steinhart K., Kirchhoff F., Münch J. Detection of SARS-CoV-2 in human breastmilk. Lancet. 2020;395:1757–1758. doi: 10.1016/s0140-6736(20)31181-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(20)31181-8</ArticleId>
            <ArticleId IdType="pmc">PMC7241971</ArticleId>
            <ArticleId IdType="pubmed">32446324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hahn F., Wangen C., Hage S., Peter A.S., Dobler G., Hurst B., Julander J., Fuchs J., Ruzsics Z., Uberla K., et al.  IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro. Viruses. 2020;12:1394.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffmann H.H., Kunz A., Simon V.A., Palese P., Shaw M.L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl. Acad. Sci. U S A. 2011;108:5777–5782. doi: 10.1073/pnas.1101143108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1101143108</ArticleId>
            <ArticleId IdType="pmc">PMC3078400</ArticleId>
            <ArticleId IdType="pubmed">21436031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., et al.  Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/nejmoa2021436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa2021436</ArticleId>
            <ArticleId IdType="pmc">PMC7383595</ArticleId>
            <ArticleId IdType="pubmed">32678530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W493. doi: 10.1093/nar/gkaa216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa216</ArticleId>
            <ArticleId IdType="pmc">PMC7319457</ArticleId>
            <ArticleId IdType="pubmed">32246720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai M., Iwatsuki-Horimoto K., Hatta M., Loeber S., Halfmann P.J., Nakajima N., Watanabe T., Ujie M., Takahashi K., Ito M., et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. U S A. 2020;117:16587–16595. doi: 10.1073/pnas.2009799117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2009799117</ArticleId>
            <ArticleId IdType="pmc">PMC7368255</ArticleId>
            <ArticleId IdType="pubmed">32571934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janion C. The efficiency and extent of mutagenic activity of some new mutagens of base-analogue type. Mutat. Res. 1978;56:225–234. doi: 10.1016/0027-5107(78)90189-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0027-5107(78)90189-6</ArticleId>
            <ArticleId IdType="pubmed">342940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janion C., Glickman B.W. N4-hydroxycytidine: a mutagen specific for AT to GC transitions. Mutat. Res. 1980;72:43–47. doi: 10.1016/0027-5107(80)90218-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0027-5107(80)90218-3</ArticleId>
            <ArticleId IdType="pubmed">6160396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., et al.  Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N. Engl. J. Med. 2021;386:509–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8693688</ArticleId>
            <ArticleId IdType="pubmed">34914868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jena N.R. Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19. Phys. Chem. Chem. Phys. 2020;22:28115–28122. doi: 10.1039/d0cp05297c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/d0cp05297c</ArticleId>
            <ArticleId IdType="pubmed">33290476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabinger F., Stiller C., Schmitzova J., Dienemann C., Kokic G., Hillen H.S., Hobartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021;28:740–746. doi: 10.1038/s41594-021-00651-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kärber G. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol. 1931;162:480–483. doi: 10.1007/bf01863914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/bf01863914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo S.H., Fitzgerald R., Fletcher T., Ewings S., Jaki T., Lyon R., Downs N., Walker L., Tansley-Hancock O., Greenhalf W., et al.  Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J. Antimicrob. Chemother. 2021;76:3286–3295. doi: 10.1093/jac/dkab318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkab318</ArticleId>
            <ArticleId IdType="pmc">PMC8598307</ArticleId>
            <ArticleId IdType="pubmed">34450619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim Y.J., Cubitt B., Cai Y., Kuhn J.H., Vitt D., Kohlhof H., de la Torre J.C. Novel dihydroorotate dehydrogenase inhibitors with potent interferon-independent antiviral activity against Mammarenaviruses in vitro. Viruses. 2020;12:821.</Citation>
        </Reference>
        <Reference>
          <Citation>Kreft M.E., Jerman U.D., Lasič E., Hevir-Kene N., Rižner T.L., Peternel L., Kristan K. The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. Eur. J. Pharm. Sci. 2015;69:1–9. doi: 10.1016/j.ejps.2014.12.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2014.12.017</ArticleId>
            <ArticleId IdType="pubmed">25555374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lifson N., McClintock R. Theory of use of the turnover rates of body water for measuring energy and material balance. J. Theor. Biol. 1966;12:46–74. doi: 10.1016/0022-5193(66)90185-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-5193(66)90185-8</ArticleId>
            <ArticleId IdType="pubmed">6015431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q., Gupta A., Okesli-Armlovich A., Qiao W., Fischer C.R., Smith M., Carette J.E., Bassik M.C., Khosla C. Enhancing the antiviral efficacy of RNA-dependent RNA polymerase inhibition by combination with modulators of pyrimidine metabolism. Cell Chem. Biol. 2020;27:668–677.e9. doi: 10.1016/j.chembiol.2020.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2020.05.002</ArticleId>
            <ArticleId IdType="pmc">PMC7241336</ArticleId>
            <ArticleId IdType="pubmed">32442424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luban J., Sattler R.A., Mühlberger E., Graci J.D., Cao L., Weetall M., Trotta C., Colacino J.M., Bavari S., Strambio-De-Castillia C., et al.  The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res. 2021;292:198246. doi: 10.1016/j.virusres.2020.198246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virusres.2020.198246</ArticleId>
            <ArticleId IdType="pmc">PMC7690341</ArticleId>
            <ArticleId IdType="pubmed">33249060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manns M.P., Buti M., Gane E., Pawlotsky J.-M., Razavi H., Terrault N., Younossi Z. Hepatitis C virus infection. Nat. Rev. Dis. Primers. 2017;3:17006. doi: 10.1038/nrdp.2017.6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2017.6</ArticleId>
            <ArticleId IdType="pubmed">28252637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCray P.B., Jr., Pewe L., Wohlford-Lenane C., Hickey M., Manzel L., Shi L., Netland J., Jia H.P., Halabi C., Sigmund C.D., et al.  Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:813–821. doi: 10.1128/jvi.02012-06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jvi.02012-06</ArticleId>
            <ArticleId IdType="pmc">PMC1797474</ArticleId>
            <ArticleId IdType="pubmed">17079315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meister T.L., Fortmann J., Todt D., Heinen N., Ludwig A., Brüggemann Y., Elsner C., Dittmer U., Steinmann J., Pfaender S., Steinmann E. Comparable environmental stability and disinfection profiles of the currently circulating SARS-CoV-2 variants of concern B.1.1.7 and B.1.351. J. Infect. Dis. 2021;224:420–424. doi: 10.1093/infdis/jiab260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab260</ArticleId>
            <ArticleId IdType="pmc">PMC8243362</ArticleId>
            <ArticleId IdType="pubmed">33993274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyerholz D.K., Beck A.P. Fundamental concepts for semiquantitative tissue scoring in translational research. ILAR J. 2018;59:13–17. doi: 10.1093/ilar/ily025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ilar/ily025</ArticleId>
            <ArticleId IdType="pmc">PMC6927897</ArticleId>
            <ArticleId IdType="pubmed">30715381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muehler A., Kohlhof H., Groeppel M., Vitt D. Safety, tolerability and pharmacokinetics of Vidofludimus calcium (IMU-838) after single and multiple ascending oral doses in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 2020;45:557–573. doi: 10.1007/s13318-020-00623-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13318-020-00623-7</ArticleId>
            <ArticleId IdType="pmc">PMC7511286</ArticleId>
            <ArticleId IdType="pubmed">32361977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muehler A., Peelen E., Kohlhof H., Gröppel M., Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 2020;43:102129. doi: 10.1016/j.msard.2020.102129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.102129</ArticleId>
            <ArticleId IdType="pubmed">32428844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munier-Lehmann H., Vidalain P.O., Tangy F., Janin Y.L. On dihydroorotate dehydrogenases and their inhibitors and uses. J. Med. Chem. 2013;56:3148–3167. doi: 10.1021/jm301848w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm301848w</ArticleId>
            <ArticleId IdType="pubmed">23452331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Negishi K., Harada C., Ohara Y., Oohara K., Nitta N., Hayatsu H. N4-aminocytidine, a nucleoside analog that has an exceptionally high mutagenic activity. Nucleic Acids Res. 1983;11:5223–5233. doi: 10.1093/nar/11.15.5223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/11.15.5223</ArticleId>
            <ArticleId IdType="pmc">PMC326252</ArticleId>
            <ArticleId IdType="pubmed">6224136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oladunni F.S., Park J.-G., Pino P.A., Gonzalez O., Akhter A., Allué-Guardia A., Olmo-Fontánez A., Gautam S., Garcia-Vilanova A., Ye C., et al.  Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 2020;11:6122. doi: 10.1038/s41467-020-19891-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-19891-7</ArticleId>
            <ArticleId IdType="pmc">PMC7705712</ArticleId>
            <ArticleId IdType="pubmed">33257679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N.C.J.E., Morin M.J., Szewczyk L.J., Painter G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 2021;65:e02428-20. doi: 10.1128/aac.02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.02428-20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peter A.S., Roth E., Schulz S.R., Fraedrich K., Steinmetz T., Damm D., Hauke M., Richel E., Mueller-Schmucker S., Habenicht K., et al.  A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. Eur. J. Immunol. 2021 doi: 10.1002/eji.202149374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.202149374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popowska E., Janion C. N4-hydroxycytidine-a new mutagen of a base analogue type. Biochem. Biophys. Res. Commun. 1974;56:459–466. doi: 10.1016/0006-291x(74)90864-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-291x(74)90864-x</ArticleId>
            <ArticleId IdType="pubmed">4596060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prince T., Donovan-Banfield I.A., Goldswain H., Penrice-Randal R., Turtle L., Fletcher T., Khoo S., Hiscox J.A. Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 variants of concern (VOCs) and its therapeutic window in a human lung cell model. bioRxiv. 2021 doi: 10.1101/2021.11.23.469695. Preprint at.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.11.23.469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pruijssers A.J., Denison M.R. Nucleoside analogues for the treatment of coronavirus infections. Curr. Opin. Virol. 2019;35:57–62. doi: 10.1016/j.coviro.2019.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coviro.2019.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC7102703</ArticleId>
            <ArticleId IdType="pubmed">31125806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyrc K., Bosch B.J., Berkhout B., Jebbink M.F., Dijkman R., Rottier P., van der Hoek L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob. Agents Chemother. 2006;50:2000–2008. doi: 10.1128/aac.01598-05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.01598-05</ArticleId>
            <ArticleId IdType="pmc">PMC1479111</ArticleId>
            <ArticleId IdType="pubmed">16723558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynard O., Nguyen X.N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V.E. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses. 2015;7:6233–6240. doi: 10.3390/v7122934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v7122934</ArticleId>
            <ArticleId IdType="pmc">PMC4690858</ArticleId>
            <ArticleId IdType="pubmed">26633464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riek A., Petow S., Speakman J.R., Schrader L. Daily energy expenditure and water turnover in two breeds of laying hens kept in floor housing. Animal. 2021;15:100047. doi: 10.1016/j.animal.2020.100047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.animal.2020.100047</ArticleId>
            <ArticleId IdType="pubmed">33515991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenke K., Hansen F., Schwarz B., Feldmann F., Haddock E., Rosenke R., Barbian K., Meade-White K., Okumura A., Leventhal S., et al.  Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat. Commun. 2021;12:2295. doi: 10.1038/s41467-021-22580-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-22580-8</ArticleId>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saccon E., Chen X., Mikaeloff F., Rodriguez J.E., Szekely L., Vinhas B.S., Krishnan S., Byrareddy S.N., Frisan T., Végvári Á., et al.  Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2. iScience. 2021;24:102420. doi: 10.1016/j.isci.2021.102420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.isci.2021.102420</ArticleId>
            <ArticleId IdType="pmc">PMC8056843</ArticleId>
            <ArticleId IdType="pubmed">33898942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salganik R.I., Vasjunina E.A., Poslovina A.S., Andreeva I.S. Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt. Mutat. Res. 1973;20:1–5. doi: 10.1016/0027-5107(73)90091-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0027-5107(73)90091-2</ArticleId>
            <ArticleId IdType="pubmed">4586551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schultz D.C., Johnson R.M., Ayyanathan K., Miller J., Whig K., Kamalia B., Dittmar M., Weston S., Hammond H.L., Dillen C., et al.  Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature. 2022;604:134–140. doi: 10.1038/s41586-022-04482-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-022-04482-x</ArticleId>
            <ArticleId IdType="pubmed">35130559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schafer A., Dinnon K.H., 3rd, Stevens L.J., et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Speakman J.R. How should we calculate CO2 production in doubly labeled water studies of animals? Funct. Ecol. 1993;7:746–750.</Citation>
        </Reference>
        <Reference>
          <Citation>Speakman J.R.  Springer; 1997. Doubly-Labelled Water: Theory and Practice.</Citation>
        </Reference>
        <Reference>
          <Citation>Stegmann K.M., Dickmanns A., Gerber S., Nikolova V., Klemke L., Manzini V., Schlösser D., Bierwirth C., Freund J., Sitte M., et al.  The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Res. 2021;302:198469. doi: 10.1016/j.virusres.2021.198469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virusres.2021.198469</ArticleId>
            <ArticleId IdType="pmc">PMC8180352</ArticleId>
            <ArticleId IdType="pubmed">34090962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stegmann K.M., Dickmanns A., Heinen N., Groß U., Görlich D., Pfaender S., Dobbelstein M. N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication. bioRxiv. 2021 doi: 10.1101/2021.06.28.450163. Preprint at.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.06.28.450163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuyver L.J., Whitaker T., McBrayer T.R., Hernandez-Santiago B.I., Lostia S., Tharnish P.M., Ramesh M., Chu C.K., Jordan R., Shi J., et al.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 2003;47:244–254. doi: 10.1128/aac.47.1.244-254.2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.47.1.244-254.2003</ArticleId>
            <ArticleId IdType="pmc">PMC149013</ArticleId>
            <ArticleId IdType="pubmed">12499198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S.H., Chen Q., Gu H.J., Yang G., Wang Y.X., Huang X.Y., Liu S.S., Zhang N.N., Li X.F., Xiong R., et al.  A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28:124–133.e4. doi: 10.1016/j.chom.2020.05.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2020.05.020</ArticleId>
            <ArticleId IdType="pmc">PMC7250783</ArticleId>
            <ArticleId IdType="pubmed">32485164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V., Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., et al.  Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443. doi: 10.1038/s41586-021-03402-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId>
            <ArticleId IdType="pubmed">33690265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Testoni B., Levrero M., Durantel D. Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? Gut. 2014;63:3–4. doi: 10.1136/gutjnl-2013-304528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2013-304528</ArticleId>
            <ArticleId IdType="pubmed">23661602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C., Avezum A., Lopes R.D., Bueno F.R., Silva M.V.A.O., et al.  Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–1316. doi: 10.1001/jama.2020.17021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.17021</ArticleId>
            <ArticleId IdType="pmc">PMC7489411</ArticleId>
            <ArticleId IdType="pubmed">32876695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., et al.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.J., Hart M., Natchus M.G., Painter G.R., Plemper R.K. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl. Res. 2020;218:16–28. doi: 10.1016/j.trsl.2019.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2019.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vangeel L., De Jonghe S., Maes P., Slechten B., Raymenants J., Andre E., Neyts J., Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. bioRxiv. 2021 doi: 10.1101/2021.12.27.474275. Preprint at.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.27.474275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L., Johnson C., Yao W., Kovarova M., Dinnon K., Liu H., Madden V., Krzystek H., De C., et al.  Acute SARS-CoV-2 infection is highly cytopathic, elicits a robust innate immune response and is efficiently prevented by EIDD-2801. Res. Sq. 2020 doi: 10.21203/rs.3.rs-80404/v1. rs.3.rs-80404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21203/rs.3.rs-80404/v1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L.E., Johnson C.E., Yao W., Kovarova M., Dinnon K.H., 3rd, Liu H., Madden V.J., Krzystek H.M., De C., et al.  SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–457. doi: 10.1038/s41586-021-03312-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P., Nair M.S., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. bioRxiv. 2021 doi: 10.1101/2021.01.25.428137. Preprint at.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.01.25.428137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Li P., Solanki K., Li Y., Ma Z., Peppelenbosch M.P., Baig M.S., Pan Q. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology. 2021;564:33–38. doi: 10.1016/j.virol.2021.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2021.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC8486977</ArticleId>
            <ArticleId IdType="pubmed">34619630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z., Yang L. In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery. J. Med. Virol. 2021;94:1766–1767. doi: 10.1002/jmv.27540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.27540</ArticleId>
            <ArticleId IdType="pubmed">34936106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weir J.B.D.V. New methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 1949;109:1–9. doi: 10.1113/jphysiol.1949.sp004363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.1949.sp004363</ArticleId>
            <ArticleId IdType="pmc">PMC1392602</ArticleId>
            <ArticleId IdType="pubmed">15394301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong R., Zhang L., Li S., Sun Y., Ding M., Wang Y., Zhao Y., Wu Y., Shang W., Jiang X., et al.  Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2020;11:723–739. doi: 10.1007/s13238-020-00768-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-020-00768-w</ArticleId>
            <ArticleId IdType="pmc">PMC7402641</ArticleId>
            <ArticleId IdType="pubmed">32754890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon J.J., Toots M., Lee S., Lee M.E., Ludeke B., Luczo J.M., Ganti K., Cox R.M., Sticher Z.M., Edpuganti V., et al.  Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 2018;62:e00766-18. doi: 10.1128/aac.00766-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.00766-18</ArticleId>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuen M.-F., Chen D.-S., Dusheiko G.M., Janssen H.L.A., Lau D.T.Y., Locarnini S.A., Peters M.G., Lai C.-L. Hepatitis B virus infection. Nat. Rev. Dis. Primers. 2018;4:18035. doi: 10.1038/nrdp.2018.35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2018.35</ArticleId>
            <ArticleId IdType="pubmed">29877316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Das P., Schmolke M., Manicassamy B., Wang Y., Deng X., Cai L., Tu B.P., Forst C.V., Roth M.G., et al.  Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export. J. Cell Biol. 2012;196:315–326. doi: 10.1083/jcb.201107058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201107058</ArticleId>
            <ArticleId IdType="pmc">PMC3275370</ArticleId>
            <ArticleId IdType="pubmed">22312003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Guo R., Kim S.H., Shah H., Zhang S., Liang J.H., Fang Y., Gentili M., Leary C.N.O., Elledge S.J., et al.  SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication. Nat. Commun. 2021;12:1676. doi: 10.1038/s41467-021-21903-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-21903-z</ArticleId>
            <ArticleId IdType="pmc">PMC7960988</ArticleId>
            <ArticleId IdType="pubmed">33723254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng S., Wang W., Aldahdooh J., Malyutina A., Shadbahr T., Tanoli Z., Pessia A., Tang J. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022 doi: 10.1016/j.gpb.2022.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gpb.2022.01.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S., Hill C.S., Sarkar S., Tse L.V., Woodburn B.M.D., Schinazi R.F., Sheahan T.P., Baric R.S., Heise M.T., Swanstrom R. β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 2021;224:415–419. doi: 10.1093/infdis/jiab247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
